NASDAQ · Biotechnology

PRME (PRME) Stock

$3.01 +2.03% NASDAQ: PRME Healthcare

Valuation

MetricValue
Price$3.01
Market Cap$543.66M
P/E Ratio-3.33
P/B Ratio6.81
P/S Ratio129.65
EPS (TTM)$-0.79
52-Week High$6.94
52-Week Low$2.02
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-216.06%
ROA-41.46%
ROCE-171.90%
Gross Margin-10.83%
Operating Margin-51.22%
Net Margin-49.18%
Debt/Equity1.49
Current Ratio4.89

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$3.0M$5.0M
Operating Profit$-84.0M$-117.0M$-205.0M$-202.0M$-208.0M
Net Profit$-165.0M$-122.0M$-198.0M$-196.0M$-201.0M
EPS$-1.92$-1.46$-2.18$-1.65$-1.35
Op Margin———-6787.4%-4498.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$302.0M$360.0M$194.0M$298.0M$343.0M
Total Liabilities$62.0M$44.0M$61.0M$144.0M$222.0M
Cash$185.0M$188.0M$42.0M$182.0M$63.0M
Borrowings$10.0M$29.0M$14.0M$41.0M$116.0M

Latest News

Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM) Insider Monkey · Jul 15, 2026 Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics Insider Monkey · Jul 15, 2026 Cathie Wood Dumps AMD, Doubles Down on Meta Stock GuruFocus.com · Jul 10, 2026 Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? Simply Wall St. · Jul 9, 2026 Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle Investor's Business Daily · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-34.0M$-132.0M$-165.0M$-123.0M$-163.0M
Investing Cash Flow$-78.0M$-63.0M$10.0M$61.0M$-113.0M
Financing Cash Flow$-1.0M$-4.0M$0$26.0M$12.0M
Net Cash Flow$162.0M$3.0M$-146.0M$141.0M$-120.0M
Free Cash Flow$-38.0M$-148.0M$-174.0M$-130.0M$-167.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-2.41
FCF Yield-30.35%
Quick Ratio3.80
Interest Coverage—
Return 1Y-35.99%
Return 3Y-79.60%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCAX $27.81 +2.92% -7.37 $1.52B 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
KURA $9.57 +3.13% -2.90 $849.57M 0.00%
MRVI $6.90 +3.06% -4.48 $1.90B 0.00%
PROKProKidney Corp. $1.56 +3.67% -2.73 $522.87M 0.00%

About PRME

PRME is led by CEO Allan Reine, employs 214 people, headquartered in US, publicly traded since 2022.

PRME stock trades at $3.01 with a market capitalization of $543.66M. The stock is valued at a price-to-earnings (P/E) ratio of -3.33, price-to-book of 6.81, price-to-sales of 129.65. Over the past 52 weeks the stock has ranged between $2.02 and $6.94, and currently trades 56.6% below its 52-week high.

On profitability, PRME generates a return on equity (ROE) of -216.06%, return on capital employed of -171.90%, an operating margin of -51.22%, a net profit margin of -49.18%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides